Quick Summary

Sophora flavescens, a traditional Chinese medicinal herb, contains bioactive alkaloids such as matrine and sophocarpine with potential pharmacological effects including immunomodulation, anti-inflammatory, anticancer, antiviral, and analgesic activities. Clinical evidence largely originates from randomized controlled trials (RCTs) and systematic reviews focusing on its use as an adjunctive therapy combined with conventional treatments in various cancers, inflammatory and infectious diseases, and chronic conditions. The evidence base includes meta-analyses showing improvements in immune function, symptom relief, and reduced chemotherapy-related adverse effects, but often with variations in study quality and the necessity for larger, high-quality trials to confirm long-term efficacy and safety.

What is it?

Sophora flavescens is a plant commonly used in traditional Chinese medicine. It is known for containing various alkaloids that have been studied for their biological activity. Extracts and preparations derived from this herb, such as Compound Kushen Injection and Kushen gel, are utilized primarily as adjuncts to conventional therapies.

Traditional Uses

Sophora flavescens has traditionally been used to treat a range of conditions including inflammatory diseases, infections, cancers, skin disorders (like eczema), and pain related to tumor metastasis. Its use often involves combination with other treatments in traditional Chinese medical practice.

Active Compounds

  • Matrine: An alkaloid studied for anti-inflammatory and anticancer properties.
  • Sophocarpine: Another key alkaloid with potential pharmacological effects including antiviral and immunomodulatory activities.

Potential Benefits with Evidence Levels

  • Adjunctive treatment for advanced colorectal cancer (Moderate-quality evidence): Compound Kushen Injection combined with chemotherapy may improve response rates, enhance immune function (increased CD3+, CD4+, NK cells; decreased CD8+), and reduce chemotherapy-related adverse effects (pmid:38853681), (pmid:40248100).
  • Immune function enhancement in primary liver cancer (Low to moderate-quality evidence): Compound Kushen Injection plus conventional therapy improved immune parameters and clinical responses, with fewer adverse effects (pmid:41800103).
  • Treatment of high-risk human papillomavirus (HR-HPV) infection (Low-quality evidence): Kushen gel improved HPV clearance and decreased viral load and recurrence with mild adverse events (pmid:41281996).
  • Reduction of bone neuropathic pain induced by tumor metastasis (Low-quality evidence): Sophora preparations may decrease pain intensity and improve patient functioning (pmid:39629083).
  • Adjunct therapy for diabetic nephropathy (Low to moderate-quality evidence): Jinlida granules including Sophora improved kidney function markers, glycemic and lipid metabolism, and inflammatory markers (pmid:41767388).
  • Treatment of chronic eczema (Moderate-quality evidence): Runzao Zhiyang capsules combined with antihistamines improved eczema symptoms and reduced drowsiness (pmid:41465894).
  • Therapeutic effect in inflammatory bowel diseases (Preclinical and low-quality evidence): Sophora extracts and oxymatrine showed anti-inflammatory effects in animal models (pmid:41394814), (pmid:40370726).
  • Anticancer effects particularly in breast cancer (Preclinical and limited clinical evidence): Matrine and related alkaloids may induce cancer cell apoptosis and inhibit proliferation; clinical data are limited (pmid:40564074), (pmid:40989842).

Side Effects

  • Mild and self-limiting reactions, such as transient vaginal burning with topical Kushen gel use.
  • Reduced chemotherapy-related toxicities like nausea, vomiting, leukopenia, and myelosuppression reported in adjunctive use.
  • Potential hepatotoxicity observed at supra-therapeutic doses in animal studies.
  • No serious adverse drug events reported in clinical meta-analyses.

Drug Interactions

No direct evidence of drug interactions has been reported. Sophora preparations are often used adjunctively with chemotherapy and antiviral agents without noted adverse interactions. However, caution is advised until thorough pharmacokinetic and interaction studies are available.

Who Should Avoid It?

Due to potential hepatotoxicity at high doses in preclinical studies, patients with liver impairment should exercise caution. There is no well-documented contraindication, but limited data exist. Pregnant or breastfeeding women should avoid use or only use under medical guidance due to lack of safety data.

Evidence Limitations

  • Many clinical trials have small sample sizes, lack blinding, placebo controls, and have heterogeneous interventions.
  • Long-term efficacy and safety data are limited or absent.
  • Many findings involve combination therapies, making it difficult to attribute effects solely to Sophora.
  • Evidence quality varies from low to moderate; high-quality, larger randomized controlled trials are needed.
  • Preclinical animal and in vitro data require cautious extrapolation to human effects.

References

Last Reviewed

June 2024

Information Disclaimer: This page is for informational purposes only and does not constitute medical advice. The use of Sophora flavescens should be discussed with a qualified healthcare professional, especially for those with pre-existing conditions or those taking other medications. More high-quality research is needed to fully understand its efficacy and safety.